Article · Wikipedia archive · Last revised Jun 26, 2026

Proterguride

Proterguride, also known as 6-propylterguride or 6-propyl-9,10-dihydrolisuride, is a dopamine agonist of the ergoline family described as a prolactin inhibitor and antiparkinsonian agent which was never marketed. It is closely structurally related to certain other ergolines like terguride and lisuride. Besides dopamine receptors, the drug also interacts with serotonin, adrenergic, and histamine receptors. Proterguride was first described in the literature by at least 1981.

Last revised
Jun 26, 2026
Read time
≈ 1 min
Length
295 w
Citations
9
Source
Wikipedia ↗
Proterguride
Clinical data
Other namesVUFB-13416; VUFB13416; ZK-39437; ZK39437; 6-Propylterguride; 6-Propyl-9,10-dihydrolisuride; N,N-Diethyl-N'-(6-propylergolin-8α-yl)urea
Drug classDopamine agonist; Prolactin inhibitor; Antiparkinsonian agent
ATC code
  • None
Identifiers
  • 3-[(6aR,9S,10aR)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H32N4O
Molar mass368.525 g·mol−1
3D model (JSmol)
  • CCCN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)NC(=O)N(CC)CC
  • InChI=1S/C22H32N4O/c1-4-10-26-14-16(24-22(27)25(5-2)6-3)12-18-17-8-7-9-19-21(17)15(13-23-19)11-20(18)26/h7-9,13,16,18,20,23H,4-6,10-12,14H2,1-3H3,(H,24,27)/t16-,18+,20+/m0/s1
  • Key:FCRJELOYDVBTGW-ILZDJORESA-N

Proterguride (INNTooltip International Nonproprietary Name; developmental code names VUFB-13416, ZK-39437), also known as 6-propylterguride or 6-propyl-9,10-dihydrolisuride, is a dopamine agonist of the ergoline family described as a prolactin inhibitor and antiparkinsonian agent which was never marketed.12345 It is closely structurally related to certain other ergolines like terguride and lisuride.14 Besides dopamine receptors, the drug also interacts with serotonin, adrenergic, and histamine receptors.5 Proterguride was first described in the literature by at least 1981.1

See also

See also

References

References

  1. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. Retrieved 30 June 2025.
  2. Milne G (8 May 2018). Drugs: Synonyms and Properties. Routledge. ISBN 978-1-351-78990-5. Retrieved 30 June 2025.
  3. Negwer M (2001). Organic-chemical Drugs and Their Synonyms: An International Survey. Wiley-VCH. ISBN 978-3-527-30247-5. Retrieved 30 June 2025.
  4. Ita K (June 2017). "Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases". Journal of Drug Targeting. 25 (5): 406–419. doi:10.1080/1061186X.2016.1245310. PMID 27701893. Proterguride (N6-propylterguride or N6-propyldihydrolisuride) is an ergoline derivative with potent dopaminergic activity [124, 125]. It has been reported that strong dopaminergic activity can be achieved at plasma concentrations below 50 pg/mL [125]. Physiologic dopamine receptor stimulation in the human striatum can be simulated by continuous administration of proterguride (PT) [125].
  5. Schurad B, Horowski R, Jähnichen S, Görnemann T, Tack J, Pertz HH (April 2006). "Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptors". Life Sciences. 78 (20): 2358–2364. doi:10.1016/j.lfs.2005.09.046. PMID 16310806.